[Blood component therapy after conversion to erythrocyte concentrate with added solutions]

Area of Science:

• Hematology
• Transfusion Medicine
• Blood Banking

Context:

• National quality standards mandated a transition from the conventional double-bag system (CPDA-1 anticoagulant) to a 4-bag system with additive solution, buffy-coat free.
• Logistical challenges led to the discontinuation of fresh blood production, necessitating alternative strategies for blood component supply.

Purpose:

• To evaluate the acceptance and identify potential drawbacks of the new 4-bag blood product system and the cessation of fresh blood production.
• To assess the clinical implications and logistical adjustments associated with these significant changes in blood supply across multiple healthcare facilities.

Summary:

• A post-marketing surveillance study involving approximately 30 hospitals indicated general acceptance of the 4-bag system and the shift away from fresh blood.
• No major issues were reported concerning transfusion techniques, albumin replacement, or bleeding tendencies. However, pediatric units encountered challenges with low protein levels during exchange transfusions.
• The discontinuation of fresh blood was noted by some institutions, but the combination of red blood cells, fresh frozen plasma, and platelet concentrates was well-received as a replacement.

Impact:

• The study confirms the successful implementation of updated blood product systems, meeting enhanced national quality requirements.
• Identified minor challenges in specific pediatric applications highlight areas for potential future optimization in blood component therapy.
• Demonstrates the adaptability of clinical practices to evolving blood banking standards and component availability.